Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: A meta-analysis

Human Reproduction Update

Volumn 17, Issue 2, 2011, Pages 184-196

  Sterrenburg, M D ^a   Veltman Verhulst, S M ^a   Eijkemans, M J C ^a   Hughes, E G ^b   Macklon, N S ^a,c   Broekmans, F J ^a   Fauser, B C J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

IVF; Meta analysis; Ovarian stimulation; RCT; recFSH

Indexed keywords

RECOMBINANT FOLLITROPIN;

CRYOPRESERVATION; DRUG DOSE COMPARISON; FEMALE; FERTILIZATION IN VITRO; HUMAN; MENSTRUAL CYCLE; META ANALYSIS; OOCYTE; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ADULT; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; HUMANS; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; RECOMBINANT PROTEINS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 79951759817     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmq041     Document Type: Review

References (30)

1. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 2003;9:275-289.
2. Baart EB, Martini E, Eijkemans MJ, Van Opstal D, Beckers NG, Verhoeff A, Macklon NS, Fauser BC. Milder ovarian stimulation for in vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Hum Reprod 2007;22:980-988.
3. Cahill DJ, Wardle PG. Management of infertility. BMJ 2002;325:28-32.
4. Cavagna M, Dzik A, Freitas GC, Soares JB, De Pawn K, Sales ALM, Andrade PC, Mantese JC, Gebrim LH. Comparison of 150 and 225 IU of follitropin-(beta) in a fixed-dose regimen for ovarian stimulation using a depot formulation of GnRH agonist: a prospective randomized clinical trial. J Bras Reproducao Assistida 2006;10:21-24.
5. de Jong D, Macklon NS, Fauser BC. A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the 'follicle-stimulating hormone window'combined with the gonadotropin-releasing hormone antagonist cetrorelix. Fertil Steril 2000;73:1051-1054.
6. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002;8:559-577.
7. Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 1997;18:71-106.
8. Fauser BC, Diedrich K, Devroey P, Evian Annual Reproduction Workshop Group 2007. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update 2008;14:1-14.
9. Heijnen EM, Eijkemans MJ, De Klerk C, Polinder S, Beckers NG, Klinkert ER, Broekmans FJ, Passchier J, Te Velde ER, Macklon NS et al. A mild treatment strategy for in vitro fertilisation: a randomised non-inferiority trial. Lancet 2007; 369:743-749.
10. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
11. Hohmann FP, Macklon NS, Fauser BC. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab 2003;88:166-173.
12. Hoomans EH, Mulder BB, Asian Purgeon Study Group. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. J Assist Reprod Genet 2002;19:470-476.
13. Huirne JA, Lambalk CB. Gonadotropin-releasing-hormone-receptor antagonists. Lancet 2001;358:1793-1803.
14. Karlsson MO, Wade JR, Loumaye E, Munafo A. A population model for the follicular growth in women treated with follicle stimulating hormone. Clin Pharmacol Ther 1997;62:665-674.
15. Latin-American Puregon IVF Study Group. A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization. Fertil Steril 2001;76: 950-956.
16. Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev 2006;27:170-207.
17. Malizia BA, Hacker MR, Penzias AS. Cumulative live-birth rates after in vitro fertilization. N Engl J Med 2009;360:236-243.
18. Nargund G, Fauser BC, Macklon NS, OmbeletW, Nygren K, Frydman R, Rotterdam ISMAAR Consensus Group on Terminology for Ovarian Stimulation for IVF. The ISMAAR proposal on terminology for ovarian stimulation for IVF. Hum Reprod 2007;22:2801-2804.
19. Olivennes F, Howles CM, Borini A, Germond M, Trew G, Wikland M, Zegers-Hochschild F, Saunders H, Alam V, CONSORT study group. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. Reprod Biomed Online 2009;18:195-204.
20. Out HJ, Lindenberg S, Mikkelsen AL, Eldar-Geva T, Healy DL, Leader A, Rodriguez-Escudero FJ, Garcia-Velasco JA, Pellicer A. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. Hum Reprod 1999;14:622-627.
21. Out HJ, Braat DD, Lintsen BM, Gurgan T, Bukulmez O, Gokmen O, Keles G, Caballero P, Gonzalez JM, Fabregues F et al. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation. Hum Reprod 2000;15:29-35.
22. Out HJ, David I, Ron-El R, Friedler S, Shalev E, Geslevich J, Dor J, Shulman A, Ben-Rafael Z, Fisch B et al. A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles. Hum Reprod 2001;16:1104-1109.
23. Out HJ, Rutherford A, Fleming R, Tay CC, Trew G, Ledger W, Cahill D. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Hum Reprod 2004;19:90-95.
24. Popovic-Todorovic B, Loft A, Bredkjaeer HE, Bangsboll S, Nielsen IK, Andersen AN. A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Hum Reprod 2003a;18:2275-2282.
25. Popovic-Todorovic B, Loft A, Lindhard A, Bangsboll S, Andersson AM, Andersen AN. A prospective study of predictive factors of ovarian response in 'standard' IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram. Hum Reprod 2003b; 18:781-787.
26. Pruksananonda K, Suwajanakorn S, Sereepapong W, Virutamasen P. Comparison of two different fixed doses of follitropin-beta in controlled ovarian hyperstimulation: a prospective randomized, double blind clinical trial. J Med Assoc Thai 2004;87:1151-1155.
27. Tan SL, Child TJ, Cheung AP, Fluker MR, Yuzpe A, Casper R, Leung P, Cadesky K, Davis VJ. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon) in women undergoing controlled ovarian hyperstimulation for IVF treatment. J Assist Reprod Genet 2005;22:81-88.
28. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002;21:589-624.
29. Wechowski J, Connolly M, Schneider D, McEwan P, Kennedy R. Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha. Fertil Steril 2009;91:1067-1076.
30. Wikland M, Bergh C, Borg K, Hillensjo T, Howles CM, Knutsson A, Nilsson L, Wood M. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Hum Reprod 2001;16:1676-1681.